Vext Science, Inc. operates in the cannabis industry, focusing on agricultural technology and property management. The company shows strengths with a solid gross margin of 55.3% and a strong EBITDA margin of 39.4%, indicating effective cost management. However, concerns arise from a negative net margin of -2.6% and low liquidity ratios (current ratio at 0.97 and quick ratio at 0.66), suggesting potential cash flow issues. Despite high margins, the low stock price of $0.26 reflects market skepticism about profitability and growth prospects.
Loading financial metrics...
Company posted a loss of $-14.4M over the last year, representing 28.4% of revenue.
Debt of $33.8M is 7.4x the company's cash position of $4.5M.
Revenue growing at 14.8% YoY, outpacing typical market growth rates.
Gross margin expanded by 8.5 percentage points, indicating improved pricing power or cost efficiency.
Strong free cash flow margin of 14.3% provides substantial resources for dividends, buybacks, or reinvestment.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)